Therapy of Ocular Behçet Disease

References

• Saka T, Takeno M. New approaches to Behçet's disease. Exp Opin Invest Drugs. 2000;9:1993–2005
   PubMedGoogle Scholar
• Takeuchi, M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmol. 2005;243(11):1147–1152
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol. 2007;91:1578–1582
   PubMedGoogle Scholar
• Tugal-Tutkun I, Cingü K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169–1177
   PubMed Web of Science ®Google Scholar
• Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behçet disease. Ocul Immunol Inflamm. 2009;17:41–46
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322:281–285
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241–243
   PubMed Web of Science ®Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988;20:136–143
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1:1093–1096
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon a combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J. 2002;4:928–930
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50:593–597
   PubMed Web of Science ®Google Scholar
• Toker E, Kazokoğlu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002;86:521–523
   PubMed Web of Science ®Google Scholar
• Yalçindag FN, Can E, Ozdemir O. Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease. Ann Ophthalmol (Skokie). 2007;39:194–197
   PubMedGoogle Scholar
• Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol. 2004;138:289–291
   PubMed Web of Science ®Google Scholar
• Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395–401
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111–136
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44:2686–2692
   PubMed Web of Science ®Google Scholar
• Masuda K, Urayama A, Kogure M, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1:1093–1096
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769–774
   PubMed Web of Science ®Google Scholar
• Taylor SR, Singh J, Menezo V, et al. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152:1059–1066
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken). 2010;62:1733–1738
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26:S84–S90
   PubMed Web of Science ®Google Scholar
• Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs. 2003;63:1535–1548
   PubMedGoogle Scholar
• Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease: Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc. 1991;23:3343–3346
   PubMed Web of Science ®Google Scholar
• Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752–760
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–1421
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tüzün E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29:S64–S67
   PubMed Web of Science ®Google Scholar
• Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol. 1990;74:353–357
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm. 2001;9:219–229
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139:177–184
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Al-Obeidan SS, Kangave D, et al. CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology. 2011;216:1004–1009
   PubMed Web of Science ®Google Scholar
• Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–1549
   PubMed Web of Science ®Google Scholar
• Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine. 2003;24:210–218
   PubMed Web of Science ®Google Scholar
• Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–132
   PubMed Web of Science ®Google Scholar
• Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNF- α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002;11:87–93
   PubMed Web of Science ®Google Scholar
• Bardak Y, Aridogan BC. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53–58
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255
   PubMed Web of Science ®Google Scholar
• Greiner K, Murphy CC, Willermain F, et al. Anti-TNF a therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170–176
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Behçet's disease. Ann Intern Med. 2004;140:404–406
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum. 2005;52:2478–2484
   PubMed Web of Science ®Google Scholar
• Ohno S, Makamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368
   PubMed Web of Science ®Google Scholar
• Lantbier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in Behçet's disease: long term follow-up in four patients. Press Med. 2005;34:916–918
   PubMedGoogle Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22:S14–S16
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26:83–92
   PubMedGoogle Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–1164
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int. 2008;29:53–57
   PubMed Web of Science ®Google Scholar
• Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191–196
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol. 2008;146:845–850
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF- α therapy in seven patients with Behçet's disease: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474–484
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease. Ocul Immunol Inflamm. 2012;20:193–197
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocul Immunol Inflamm. 2012;20:198–202
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet's disease. Arch Ophthalmol. 2012;130:592–598
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295–296
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cycstoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650
   PubMed Web of Science ®Google Scholar
• Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with Behçet's disease. J Ocul Pharmacol Ther. 2009;25:467–470
   PubMedGoogle Scholar
• Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360–361
   PubMedGoogle Scholar
• Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Report Ophthalmol. 2011;2:189–192
   PubMedGoogle Scholar
• Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol. 2007;25:S65–S69
   Google Scholar
• Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081–1087
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis. 2007;66:136–137
   PubMed Web of Science ®Google Scholar
• Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol. 2005;32:181–183
   PubMed Web of Science ®Google Scholar
• Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577–581
   PubMedGoogle Scholar
• Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to metrotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, pacebo-controlled trial. Arthritis Rheum. 2005;51:27–35
   Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129–2134
   PubMed Web of Science ®Google Scholar
• Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13:5238–5244
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–1831
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet's disease. Ocul Immunol Inflamm. 2010;18:226–232
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond). 2007;21:824–825
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet's disease-related uveitis. Rheumatol Int. 2011;31:243–245
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54–S57
   PubMed Web of Science ®Google Scholar
• Mesquida M, Victoria Hernández M, Llorenç V, et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160–162
   PubMed Web of Science ®Google Scholar
• Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007;13:543–551
   PubMed Web of Science ®Google Scholar
• Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN teatment. J Immunol. 1993;150:4687–4692
   PubMed Web of Science ®Google Scholar
• Treusch M, Vonthein R, Baur M, et al. Influence of human recombinant interferon-alpha2a (rhIFN- α 2a) on altered lymphocyte subpopulations and monocytes in Behçet's disease. Rheumatology (Oxford). 2004;43:1275–1282
   PubMed Web of Science ®Google Scholar
• Kötter I, Deuter C, Stübiger N, Zierhut M. Interferon-a (IFN-a) application versus tumor necrosis factor-α antagonism for ocular Behçet's disease: focusing more on IFN. J Rheumatol. 2005;32:1633; author reply 1634
   PubMed Web of Science ®Google Scholar
• Yang DS, Galatowicz G, Calder VL. Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behçet's disease. Poster No 1535 ARVO 2009
   Google Scholar
• Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol. 2005;141:865–868
   PubMedGoogle Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13:335–351
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320–355
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefe's Arch Clin Exp Ophthalmol. 2006;244:1692–1695
   PubMed Web of Science ®Google Scholar
• Stübiger N, Kötter I, Zierhut M. Complete regression of retinal neovascularisation after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol. 2000;84:1437–1438
   Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol. 2006;50:256–265
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844
   PubMed Web of Science ®Google Scholar
• Krause L, Altenburg A, Pleyer U, et al. Long-term visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-α-2a. J Rheumatol. 2008;35:896–903
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62:2796–2805
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Ret Eye Res 2008;27:111–136
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrosprective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61
   PubMed Web of Science ®Google Scholar
• Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer. 1990;65:2237–2242
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter CME, Stübiger N, et al. Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247:675–680
   PubMed Web of Science ®Google Scholar
• Onal S, Savar F, Akman M, Kazokoglu H. Vision- and health-related quality of life in patients with Behçet uveitis. Arch Ophthalmol. 2010;128:1265–1271
   PubMedGoogle Scholar
• Sakai T, Watanabe H, Kuroyanagi K, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis. Br J Ophthalmol. 2013;97:338–342
   PubMed Web of Science ®Google Scholar
• Gül A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81–83
   PubMedGoogle Scholar
• Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1 in autoinflammatory diseases. Arthritis Rheum. 2011;63:314–324
   PubMed Web of Science ®Google Scholar
• Savic S, Dickie LJ, Wittmann M, McDermott MF. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol. 2012;26:505–533
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–3732
   PubMed Web of Science ®Google Scholar
• Caorsi R, Federici S, Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev. 2012;12:81–86
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, et al. One target- two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol. 2013;1:94--111
   Google Scholar
• Yosipovitch G, Sholat B, Bshara J, et al. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Isr J Med Sci. 1995;31:345–348
   PubMedGoogle Scholar
• Düzgün N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int. 2005;25:1–5
   PubMed Web of Science ®Google Scholar
• Özcimen AA, Dilek K, Bingöl Ü, et al. IL-1 cluster gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet. 2011;38:295–301
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, Punzi L. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149:284–286
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis. 2012;71:1589–1591
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):115
   PubMed Web of Science ®Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open label study. Ann Rheum Dis. 2012;71:563–566
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005;52:1960–1967
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DRW. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology. 2003;42:1539–1544
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm. 2007;15:63–70
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Hoshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol. 2008;18:306–308
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease: randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298–302
   PubMed Web of Science ®Google Scholar
• Dick A, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–787
   PubMed Web of Science ®Google Scholar
• Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128:655–664
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010;42:698–702
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet. 2010;42:703–706
   PubMed Web of Science ®Google Scholar
• Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45:202–207
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Stanford MR, et al. Low prevalence of juvenile-onset Behçet's disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93:1428–1430
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Darce-Bello M, Shahram F, et al. Registries in rheumatological and musculoskeletal conditions: paediatric Behçet's disease—an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50:184–188
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114–1119
   PubMed Web of Science ®Google Scholar
• Citirik M, Berker N, Songur MS, et al. Ocular findings in childhood-onset Behçet disease. J AAPOS. 2009;13:391–395
   PubMed Web of Science ®Google Scholar
• Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behçet disease in the American Midwest. Am J Ophthalmol. 2008;146:819–827
   PubMed Web of Science ®Google Scholar
• Kramer M, Amer R, Mukamer M, et al. Uveitis in juvenile Behçet's disease:clinical course and visual outcome compared with adult patients. Eye. 2009;23:2034–2041
   PubMedGoogle Scholar
• Sungur GK, Hazirolan D, Yalvac I, et al. Clinical and demographic evaluation of Behçet disease among different paediatric age groups. Br J Ophthalmol. 2009;93:83–87
   PubMed Web of Science ®Google Scholar
• Borlu M, Uksal Ü, Ferahbas A, Evereklioglu C. Clinical features of Behçet's disease in children. Int J Dermatol. 2006;45:713–716
   PubMedGoogle Scholar
• Atmaca L, Boyvat A, Yalçindag FN, et al. Behçet disease in children. Ocul Immunol Inflamm. 2011;19:103–107
   PubMed Web of Science ®Google Scholar
• Guillame-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford). 2007;46:1570–1573
   PubMedGoogle Scholar
• Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha—a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. Rheumatology (Oxford). 2008;47:1051–1053
   PubMed Web of Science ®Google Scholar
• Yoshida A, Kaburaki T, Okinaga K, et al. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536–543
   PubMedGoogle Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26:83–92
   PubMedGoogle Scholar
• Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45:982–989
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castañeda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341–1344
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. 2008;12:611–613
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Yalçindağ FN, Ozdemir O. Intravitreal triamcinolone acetonide inthe management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451–456
   PubMed Web of Science ®Google Scholar
• Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocul Immunol Inflamm. 2013. [Epub ahead of print]
   Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553
   PubMed Web of Science ®Google Scholar
• Mirshahi A, Namavari A, Djalilian A, et al. Bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease. Ocul Immunol Inflamm. 2009;17:59–64
   PubMed Web of Science ®Google Scholar
• Erdurman FC, Durukan AH, Mumcuoğlu T, Hürmeriç V. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis. Ocul Immunol Inflamm. 2009;17:56–58
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Batioğlu F, Idil A. Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1996;234:94–99
   PubMed Web of Science ®Google Scholar
• Hu K, Lei B, Kijlstra A, et al. Male sex, erythema nodosum, and electroretinography as predictors of visual prognosis after cataract surgery in patients with Behçet disease. J Cataract Refract Surg. 2012;38:1382–1388
   PubMed Web of Science ®Google Scholar
• Berker N, Soykan E, Elgin U, Ozkan SS. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behçet's disease. Ophthalmic Surg Lasers Imag. 2004;35:215–218
   PubMedGoogle Scholar
• Krause L, Altenburg A, Bechrakis NE, et al. Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:1617–1621
   PubMedGoogle Scholar
• Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Rep Ophthalmol. 2011;2:189–192
   PubMedGoogle Scholar
• Handa T, Tsunekawa H, Zako M. Cataract surgery in Behçet's disease patients one week after infliximab administration. Case Rep Ophthalmol. 2011;2:176–178
   PubMedGoogle Scholar
• Mesquida M, Pelegrín L, Llorenç V, et al. Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. Eur J Ophthalmol. 2012 Sep 26:0. doi: 10.5301/ejo.5000194. [Epub ahead of print]
   Google Scholar
• Sullu Y, Alotaiby H, Beden U, Erkan D. Pars plana vitrectomy for ocular complications of Behçet's disease. Ophthalmic Surg Lasers Imag. 2005;36:292–297
   PubMedGoogle Scholar